Round out your CMHC educational experience by attending Professional Medical Education/Product Theater symposia focused on novel therapies. These non-certified activities are planned solely by the sponsoring organizations/companies. There are no additional fees to attend once you have registered for the 13th Annual Congress and meals or refreshments may be provided. Register for the 13th Annual CMHC today and attend these activities.


 ‌

Non-CME Lunch Symposium · Wednesday, October 24, 2018 · 12:00 – 1:00pm

Repatha® (evolocumab): Putting it into Practice

Faculty: Yehuda Handelsman, MD, FACP, FNLA, MACE

Join Dr. Handelsman for an educational presentation on the importance of Repatha® (evolocumab). Hear about his experience with Repatha and the options available for appropriate patients.

Sponsored by Amgen, Inc.


 ‌

Non-CME PME Light Bites · Wednesday, October 24, 2018 · 4:15 – 5:15pm

Gaining Access to PCSK9 Inhibitors: Dissemination of a Mobile App & More

Faculty: Seth J. Baum, MD, FASPC; Howard S. Weintraub, MD, FASPC

Learn how to access PCSK9 Inhibitors using the ASPC novel Mobile App! This innovative tool includes a simple-10-step approach, single page prior authorization and appeal letters published by the ASPC, the Association of Clinical Endocrinologists and others, valuation models of drugs, case studies, references to key papers, names of “best and worst” insurance companies in each state, links to advocacy sites, information on specialty pharmacies, and so much more.

Sponsored by Amgen, Inc. and Sanofi Regeneron.


 ‌

Non-CME PME Light Bites · Wednesday, October 24, 2018 · 5:30 – 6:30pm

Long-Term Results of Treatment Across a Broad Range of Patients With Type 2 Diabetes

Faculty: Serge Jabbour, MD

This program will cover long-term results of treatment with a sodium-glucose co-transporter 2 (SGLT2) inhibitor in patients with type 2 diabetes. Topics include: the pathophysiology of type 2 diabetes and its associated cardiometabolic risk factors; how SGLT2 inhibitors work; key efficacy and safety results, including results from longer-term follow-up, results from active-controlled studies supporting the use of SGLT2 inhibitors versus other agents, and results from a network meta-analysis of SGLT2 inhibitors; and Important Safety Information, followed by a question-and-answer session. This promotional educational activity is sponsored by Janssen Pharmaceuticals, Inc. It is not certified for continuing medical education.

Sponsored by Janssen Pharmaceuticals, Inc.


 ‌

Non-CME Dinner Symposium · Wednesday, October 24, 2018 · 6:45 – 7:45pm

The Role of VASCEPA® (icosapent ethyl): Topline Results from REDUCE-IT™

Faculty: Robert S. Busch, MD, FACE

Hear from an expert about Cardiovascular Disease Burden in the US and Clinical Evaluation of VASCEPA® (icosapent ethyl). Despite the benefits of LDL-C lowering, many patients on statin therapy remain at risk. In this presentation, data and perspectives on the role of high triglycerides as a marker of increased cardiovascular risk in patients with statin-controlled LDL-C will be discussed. The clinical development program and safety for pure EPA VASCEPA will be reviewed.

Visit the Amarin booth #414 for more information.

Financial support for this program is provided by Amarin Pharma, Inc.


 ‌

Non-CME Dinner Symposium · Friday, October 26, 2018 · 7:15 – 8:15pm

Advancements in the Management of Patients with Type 2 Diabetes: Results from a Large Cardiovascular Outcomes Trial

Faculty: Ronald D’Agostino, DO, FACC, FACP

This program will review data from a large cardiovascular outcomes trial and its impact on the management of Type 2 Diabetes.

Sponsored by Novo Nordisk